CN105237632B - 阴道毛滴虫α-actinin蛋白免疫保护性抗原、疫苗和应用 - Google Patents
阴道毛滴虫α-actinin蛋白免疫保护性抗原、疫苗和应用 Download PDFInfo
- Publication number
- CN105237632B CN105237632B CN201510742631.5A CN201510742631A CN105237632B CN 105237632 B CN105237632 B CN 105237632B CN 201510742631 A CN201510742631 A CN 201510742631A CN 105237632 B CN105237632 B CN 105237632B
- Authority
- CN
- China
- Prior art keywords
- act
- actinin
- vaccine
- glu
- trichomonas vaginalis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010063503 Actinin Proteins 0.000 title claims abstract description 39
- 102000010825 Actinin Human genes 0.000 title claims abstract description 38
- 241000224527 Trichomonas vaginalis Species 0.000 title claims abstract description 35
- 229960005486 vaccine Drugs 0.000 title claims abstract description 28
- 108091007433 antigens Proteins 0.000 title abstract description 18
- 102000036639 antigens Human genes 0.000 title abstract description 17
- 239000000427 antigen Substances 0.000 title abstract description 16
- 230000001681 protective effect Effects 0.000 title description 8
- 230000003053 immunization Effects 0.000 title description 3
- 238000002649 immunization Methods 0.000 title description 3
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 20
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 20
- 230000006798 recombination Effects 0.000 claims abstract description 18
- 238000005215 recombination Methods 0.000 claims abstract description 18
- 101710194807 Protective antigen Proteins 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 208000005448 Trichomonas Infections Diseases 0.000 claims description 8
- 206010044620 Trichomoniasis Diseases 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000000568 immunological adjuvant Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 229940023143 protein vaccine Drugs 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000014509 gene expression Effects 0.000 abstract description 14
- 230000001580 bacterial effect Effects 0.000 abstract description 10
- 238000000746 purification Methods 0.000 abstract description 9
- 230000009465 prokaryotic expression Effects 0.000 abstract description 5
- 230000009471 action Effects 0.000 abstract description 4
- 229940031626 subunit vaccine Drugs 0.000 abstract description 4
- 238000011161 development Methods 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 11
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 9
- 238000001962 electrophoresis Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000003292 glue Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- ZOXBSICWUDAOHX-GUBZILKMSA-N Glu-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCC(O)=O ZOXBSICWUDAOHX-GUBZILKMSA-N 0.000 description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 2
- NJNRBRKHOWSGMN-SRVKXCTJSA-N Lys-Leu-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O NJNRBRKHOWSGMN-SRVKXCTJSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 2
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- BSNZTJXVDOINSR-JXUBOQSCSA-N Thr-Ala-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O BSNZTJXVDOINSR-JXUBOQSCSA-N 0.000 description 2
- RWOGENDAOGMHLX-DCAQKATOSA-N Val-Lys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)N RWOGENDAOGMHLX-DCAQKATOSA-N 0.000 description 2
- 239000003716 antitrichomonal agent Substances 0.000 description 2
- 108010008355 arginyl-glutamine Proteins 0.000 description 2
- 108010038633 aspartylglutamate Proteins 0.000 description 2
- 108010092854 aspartyllysine Proteins 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 102000057593 human F8 Human genes 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 229940047431 recombinate Drugs 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- CWFMWBHMIMNZLN-NAKRPEOUSA-N (2s)-1-[(2s)-2-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]propanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CWFMWBHMIMNZLN-NAKRPEOUSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- YLTKNGYYPIWKHZ-ACZMJKKPSA-N Ala-Ala-Glu Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O YLTKNGYYPIWKHZ-ACZMJKKPSA-N 0.000 description 1
- FJVAQLJNTSUQPY-CIUDSAMLSA-N Ala-Ala-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN FJVAQLJNTSUQPY-CIUDSAMLSA-N 0.000 description 1
- JBVSSSZFNTXJDX-YTLHQDLWSA-N Ala-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N JBVSSSZFNTXJDX-YTLHQDLWSA-N 0.000 description 1
- NXSFUECZFORGOG-CIUDSAMLSA-N Ala-Asn-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NXSFUECZFORGOG-CIUDSAMLSA-N 0.000 description 1
- KIUYPHAMDKDICO-WHFBIAKZSA-N Ala-Asp-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O KIUYPHAMDKDICO-WHFBIAKZSA-N 0.000 description 1
- CXZFXHGJJPVUJE-CIUDSAMLSA-N Ala-Cys-Leu Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)O)N CXZFXHGJJPVUJE-CIUDSAMLSA-N 0.000 description 1
- CZPAHAKGPDUIPJ-CIUDSAMLSA-N Ala-Gln-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(O)=O CZPAHAKGPDUIPJ-CIUDSAMLSA-N 0.000 description 1
- NBTGEURICRTMGL-WHFBIAKZSA-N Ala-Gly-Ser Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O NBTGEURICRTMGL-WHFBIAKZSA-N 0.000 description 1
- JDIQCVUDDFENPU-ZKWXMUAHSA-N Ala-His-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CNC=N1 JDIQCVUDDFENPU-ZKWXMUAHSA-N 0.000 description 1
- JEPNLGMEZMCFEX-QSFUFRPTSA-N Ala-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](C)N JEPNLGMEZMCFEX-QSFUFRPTSA-N 0.000 description 1
- PNALXAODQKTNLV-JBDRJPRFSA-N Ala-Ile-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O PNALXAODQKTNLV-JBDRJPRFSA-N 0.000 description 1
- TZDNWXDLYFIFPT-BJDJZHNGSA-N Ala-Ile-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O TZDNWXDLYFIFPT-BJDJZHNGSA-N 0.000 description 1
- VNYMOTCMNHJGTG-JBDRJPRFSA-N Ala-Ile-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O VNYMOTCMNHJGTG-JBDRJPRFSA-N 0.000 description 1
- SOBIAADAMRHGKH-CIUDSAMLSA-N Ala-Leu-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O SOBIAADAMRHGKH-CIUDSAMLSA-N 0.000 description 1
- SUHLZMHFRALVSY-YUMQZZPRSA-N Ala-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)NCC(O)=O SUHLZMHFRALVSY-YUMQZZPRSA-N 0.000 description 1
- VCSABYLVNWQYQE-UHFFFAOYSA-N Ala-Lys-Lys Natural products NCCCCC(NC(=O)C(N)C)C(=O)NC(CCCCN)C(O)=O VCSABYLVNWQYQE-UHFFFAOYSA-N 0.000 description 1
- BTRULDJUUVGRNE-DCAQKATOSA-N Ala-Pro-Lys Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O BTRULDJUUVGRNE-DCAQKATOSA-N 0.000 description 1
- FFZJHQODAYHGPO-KZVJFYERSA-N Ala-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N FFZJHQODAYHGPO-KZVJFYERSA-N 0.000 description 1
- HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 1
- OEVCHROQUIVQFZ-YTLHQDLWSA-N Ala-Thr-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](C)C(O)=O OEVCHROQUIVQFZ-YTLHQDLWSA-N 0.000 description 1
- WNHNMKOFKCHKKD-BFHQHQDPSA-N Ala-Thr-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O WNHNMKOFKCHKKD-BFHQHQDPSA-N 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- QAODJPUKWNNNRP-DCAQKATOSA-N Arg-Glu-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O QAODJPUKWNNNRP-DCAQKATOSA-N 0.000 description 1
- RFXXUWGNVRJTNQ-QXEWZRGKSA-N Arg-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)N RFXXUWGNVRJTNQ-QXEWZRGKSA-N 0.000 description 1
- WVNFNPGXYADPPO-BQBZGAKWSA-N Arg-Gly-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O WVNFNPGXYADPPO-BQBZGAKWSA-N 0.000 description 1
- FRMQITGHXMUNDF-GMOBBJLQSA-N Arg-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N FRMQITGHXMUNDF-GMOBBJLQSA-N 0.000 description 1
- XYOVHPDDWCEUDY-CIUDSAMLSA-N Asn-Ala-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O XYOVHPDDWCEUDY-CIUDSAMLSA-N 0.000 description 1
- SLKLLQWZQHXYSV-CIUDSAMLSA-N Asn-Ala-Lys Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O SLKLLQWZQHXYSV-CIUDSAMLSA-N 0.000 description 1
- JZDZLBJVYWIIQU-AVGNSLFASA-N Asn-Glu-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JZDZLBJVYWIIQU-AVGNSLFASA-N 0.000 description 1
- OPEPUCYIGFEGSW-WDSKDSINSA-N Asn-Gly-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O OPEPUCYIGFEGSW-WDSKDSINSA-N 0.000 description 1
- OLVIPTLKNSAYRJ-YUMQZZPRSA-N Asn-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N OLVIPTLKNSAYRJ-YUMQZZPRSA-N 0.000 description 1
- LSJQOMAZIKQMTJ-SRVKXCTJSA-N Asn-Phe-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O LSJQOMAZIKQMTJ-SRVKXCTJSA-N 0.000 description 1
- XEGZSHSPQNDNRH-JRQIVUDYSA-N Asn-Tyr-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XEGZSHSPQNDNRH-JRQIVUDYSA-N 0.000 description 1
- HBUJSDCLZCXXCW-YDHLFZDLSA-N Asn-Val-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HBUJSDCLZCXXCW-YDHLFZDLSA-N 0.000 description 1
- KRXIWXCXOARFNT-ZLUOBGJFSA-N Asp-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O KRXIWXCXOARFNT-ZLUOBGJFSA-N 0.000 description 1
- QXHVOUSPVAWEMX-ZLUOBGJFSA-N Asp-Asp-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O QXHVOUSPVAWEMX-ZLUOBGJFSA-N 0.000 description 1
- QCLHLXDWRKOHRR-GUBZILKMSA-N Asp-Glu-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)N QCLHLXDWRKOHRR-GUBZILKMSA-N 0.000 description 1
- PZXPWHFYZXTFBI-YUMQZZPRSA-N Asp-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O PZXPWHFYZXTFBI-YUMQZZPRSA-N 0.000 description 1
- KHGPWGKPYHPOIK-QWRGUYRKSA-N Asp-Gly-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O KHGPWGKPYHPOIK-QWRGUYRKSA-N 0.000 description 1
- DWOGMPWRQQWPPF-GUBZILKMSA-N Asp-Leu-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O DWOGMPWRQQWPPF-GUBZILKMSA-N 0.000 description 1
- JSNWZMFSLIWAHS-HJGDQZAQSA-N Asp-Thr-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O JSNWZMFSLIWAHS-HJGDQZAQSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- SKSJPIBFNFPTJB-NKWVEPMBSA-N Cys-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CS)N)C(=O)O SKSJPIBFNFPTJB-NKWVEPMBSA-N 0.000 description 1
- LBSKYJOZIIOZIO-DCAQKATOSA-N Cys-Lys-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N LBSKYJOZIIOZIO-DCAQKATOSA-N 0.000 description 1
- 208000034423 Delivery Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- RZSLYUUFFVHFRQ-FXQIFTODSA-N Gln-Ala-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O RZSLYUUFFVHFRQ-FXQIFTODSA-N 0.000 description 1
- KVYVOGYEMPEXBT-GUBZILKMSA-N Gln-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O KVYVOGYEMPEXBT-GUBZILKMSA-N 0.000 description 1
- JFSNBQJNDMXMQF-XHNCKOQMSA-N Gln-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)N)C(=O)O JFSNBQJNDMXMQF-XHNCKOQMSA-N 0.000 description 1
- KQOPMGBHNQBCEL-HVTMNAMFSA-N Gln-His-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KQOPMGBHNQBCEL-HVTMNAMFSA-N 0.000 description 1
- FKXCBKCOSVIGCT-AVGNSLFASA-N Gln-Lys-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O FKXCBKCOSVIGCT-AVGNSLFASA-N 0.000 description 1
- BBFCMGBMYIAGRS-AUTRQRHGSA-N Gln-Val-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O BBFCMGBMYIAGRS-AUTRQRHGSA-N 0.000 description 1
- FHPXTPQBODWBIY-CIUDSAMLSA-N Glu-Ala-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FHPXTPQBODWBIY-CIUDSAMLSA-N 0.000 description 1
- RLZBLVSJDFHDBL-KBIXCLLPSA-N Glu-Ala-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O RLZBLVSJDFHDBL-KBIXCLLPSA-N 0.000 description 1
- OJGLIOXAKGFFDW-SRVKXCTJSA-N Glu-Arg-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)O)N OJGLIOXAKGFFDW-SRVKXCTJSA-N 0.000 description 1
- PVBBEKPHARMPHX-DCAQKATOSA-N Glu-Gln-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCC(O)=O PVBBEKPHARMPHX-DCAQKATOSA-N 0.000 description 1
- BUZMZDDKFCSKOT-CIUDSAMLSA-N Glu-Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BUZMZDDKFCSKOT-CIUDSAMLSA-N 0.000 description 1
- QJCKNLPMTPXXEM-AUTRQRHGSA-N Glu-Glu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O QJCKNLPMTPXXEM-AUTRQRHGSA-N 0.000 description 1
- ZWABFSSWTSAMQN-KBIXCLLPSA-N Glu-Ile-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O ZWABFSSWTSAMQN-KBIXCLLPSA-N 0.000 description 1
- QIQABBIDHGQXGA-ZPFDUUQYSA-N Glu-Ile-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O QIQABBIDHGQXGA-ZPFDUUQYSA-N 0.000 description 1
- VMKCPNBBPGGQBJ-GUBZILKMSA-N Glu-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N VMKCPNBBPGGQBJ-GUBZILKMSA-N 0.000 description 1
- IRXNJYPKBVERCW-DCAQKATOSA-N Glu-Leu-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IRXNJYPKBVERCW-DCAQKATOSA-N 0.000 description 1
- IVGJYOOGJLFKQE-AVGNSLFASA-N Glu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N IVGJYOOGJLFKQE-AVGNSLFASA-N 0.000 description 1
- YKBUCXNNBYZYAY-MNXVOIDGSA-N Glu-Lys-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O YKBUCXNNBYZYAY-MNXVOIDGSA-N 0.000 description 1
- ZIYGTCDTJJCDDP-JYJNAYRXSA-N Glu-Phe-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZIYGTCDTJJCDDP-JYJNAYRXSA-N 0.000 description 1
- HZISRJBYZAODRV-XQXXSGGOSA-N Glu-Thr-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O HZISRJBYZAODRV-XQXXSGGOSA-N 0.000 description 1
- JVYNYWXHZWVJEF-NUMRIWBASA-N Glu-Thr-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O JVYNYWXHZWVJEF-NUMRIWBASA-N 0.000 description 1
- QGAJQIGFFIQJJK-IHRRRGAJSA-N Glu-Tyr-Gln Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O QGAJQIGFFIQJJK-IHRRRGAJSA-N 0.000 description 1
- MLILEEIVMRUYBX-NHCYSSNCSA-N Glu-Val-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O MLILEEIVMRUYBX-NHCYSSNCSA-N 0.000 description 1
- VIPDPMHGICREIS-GVXVVHGQSA-N Glu-Val-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O VIPDPMHGICREIS-GVXVVHGQSA-N 0.000 description 1
- FIQQRCFQXGLOSZ-WDSKDSINSA-N Gly-Glu-Asp Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O FIQQRCFQXGLOSZ-WDSKDSINSA-N 0.000 description 1
- YYPFZVIXAVDHIK-IUCAKERBSA-N Gly-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CN YYPFZVIXAVDHIK-IUCAKERBSA-N 0.000 description 1
- ULZCYBYDTUMHNF-IUCAKERBSA-N Gly-Leu-Glu Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ULZCYBYDTUMHNF-IUCAKERBSA-N 0.000 description 1
- MHXKHKWHPNETGG-QWRGUYRKSA-N Gly-Lys-Leu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O MHXKHKWHPNETGG-QWRGUYRKSA-N 0.000 description 1
- ZWRDOVYMQAAISL-UWVGGRQHSA-N Gly-Met-Lys Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CCCCN ZWRDOVYMQAAISL-UWVGGRQHSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- BZKDJRSZWLPJNI-SRVKXCTJSA-N His-His-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O BZKDJRSZWLPJNI-SRVKXCTJSA-N 0.000 description 1
- SKYULSWNBYAQMG-IHRRRGAJSA-N His-Leu-Arg Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SKYULSWNBYAQMG-IHRRRGAJSA-N 0.000 description 1
- LVWIJITYHRZHBO-IXOXFDKPSA-N His-Leu-Thr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LVWIJITYHRZHBO-IXOXFDKPSA-N 0.000 description 1
- XDIVYNSPYBLSME-DCAQKATOSA-N His-Met-Asp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N XDIVYNSPYBLSME-DCAQKATOSA-N 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- HDODQNPMSHDXJT-GHCJXIJMSA-N Ile-Asn-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O HDODQNPMSHDXJT-GHCJXIJMSA-N 0.000 description 1
- RPZFUIQVAPZLRH-GHCJXIJMSA-N Ile-Asp-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)O)N RPZFUIQVAPZLRH-GHCJXIJMSA-N 0.000 description 1
- UDLAWRKOVFDKFL-PEFMBERDSA-N Ile-Asp-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N UDLAWRKOVFDKFL-PEFMBERDSA-N 0.000 description 1
- NKRJALPCDNXULF-BYULHYEWSA-N Ile-Asp-Gly Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O NKRJALPCDNXULF-BYULHYEWSA-N 0.000 description 1
- NPROWIBAWYMPAZ-GUDRVLHUSA-N Ile-Asp-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N NPROWIBAWYMPAZ-GUDRVLHUSA-N 0.000 description 1
- OUUCIIJSBIBCHB-ZPFDUUQYSA-N Ile-Leu-Asp Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O OUUCIIJSBIBCHB-ZPFDUUQYSA-N 0.000 description 1
- IIWQTXMUALXGOV-PCBIJLKTSA-N Ile-Phe-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)O)C(=O)O)N IIWQTXMUALXGOV-PCBIJLKTSA-N 0.000 description 1
- SAVXZJYTTQQQDD-QEWYBTABSA-N Ile-Phe-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N SAVXZJYTTQQQDD-QEWYBTABSA-N 0.000 description 1
- CIDLJWVDMNDKPT-FIRPJDEBSA-N Ile-Phe-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)N CIDLJWVDMNDKPT-FIRPJDEBSA-N 0.000 description 1
- KCTIFOCXAIUQQK-QXEWZRGKSA-N Ile-Pro-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O KCTIFOCXAIUQQK-QXEWZRGKSA-N 0.000 description 1
- YCKPUHHMCFSUMD-IUKAMOBKSA-N Ile-Thr-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N YCKPUHHMCFSUMD-IUKAMOBKSA-N 0.000 description 1
- COWHUQXTSYTKQC-RWRJDSDZSA-N Ile-Thr-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N COWHUQXTSYTKQC-RWRJDSDZSA-N 0.000 description 1
- WCNWGAUZWWSYDG-SVSWQMSJSA-N Ile-Thr-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)O)N WCNWGAUZWWSYDG-SVSWQMSJSA-N 0.000 description 1
- RMJWFINHACYKJI-SIUGBPQLSA-N Ile-Tyr-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N RMJWFINHACYKJI-SIUGBPQLSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- KWTVLKBOQATPHJ-SRVKXCTJSA-N Leu-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(C)C)N KWTVLKBOQATPHJ-SRVKXCTJSA-N 0.000 description 1
- POJPZSMTTMLSTG-SRVKXCTJSA-N Leu-Asn-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N POJPZSMTTMLSTG-SRVKXCTJSA-N 0.000 description 1
- HPBCTWSUJOGJSH-MNXVOIDGSA-N Leu-Glu-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HPBCTWSUJOGJSH-MNXVOIDGSA-N 0.000 description 1
- LLBQJYDYOLIQAI-JYJNAYRXSA-N Leu-Glu-Tyr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LLBQJYDYOLIQAI-JYJNAYRXSA-N 0.000 description 1
- HYMLKESRWLZDBR-WEDXCCLWSA-N Leu-Gly-Thr Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O HYMLKESRWLZDBR-WEDXCCLWSA-N 0.000 description 1
- CSFVADKICPDRRF-KKUMJFAQSA-N Leu-His-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CN=CN1 CSFVADKICPDRRF-KKUMJFAQSA-N 0.000 description 1
- HVHRPWQEQHIQJF-AVGNSLFASA-N Leu-Lys-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O HVHRPWQEQHIQJF-AVGNSLFASA-N 0.000 description 1
- AIRUUHAOKGVJAD-JYJNAYRXSA-N Leu-Phe-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIRUUHAOKGVJAD-JYJNAYRXSA-N 0.000 description 1
- PJWOOBTYQNNRBF-BZSNNMDCSA-N Leu-Phe-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)O)N PJWOOBTYQNNRBF-BZSNNMDCSA-N 0.000 description 1
- KLSUAWUZBMAZCL-RHYQMDGZSA-N Leu-Thr-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(O)=O KLSUAWUZBMAZCL-RHYQMDGZSA-N 0.000 description 1
- ISSAURVGLGAPDK-KKUMJFAQSA-N Leu-Tyr-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O ISSAURVGLGAPDK-KKUMJFAQSA-N 0.000 description 1
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 1
- JGAMUXDWYSXYLM-SRVKXCTJSA-N Lys-Arg-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O JGAMUXDWYSXYLM-SRVKXCTJSA-N 0.000 description 1
- HIIZIQUUHIXUJY-GUBZILKMSA-N Lys-Asp-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HIIZIQUUHIXUJY-GUBZILKMSA-N 0.000 description 1
- LMVOVCYVZBBWQB-SRVKXCTJSA-N Lys-Asp-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN LMVOVCYVZBBWQB-SRVKXCTJSA-N 0.000 description 1
- NRQRKMYZONPCTM-CIUDSAMLSA-N Lys-Asp-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NRQRKMYZONPCTM-CIUDSAMLSA-N 0.000 description 1
- IMAKMJCBYCSMHM-AVGNSLFASA-N Lys-Glu-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN IMAKMJCBYCSMHM-AVGNSLFASA-N 0.000 description 1
- XNKDCYABMBBEKN-IUCAKERBSA-N Lys-Gly-Gln Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O XNKDCYABMBBEKN-IUCAKERBSA-N 0.000 description 1
- OWRUUFUVXFREBD-KKUMJFAQSA-N Lys-His-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O OWRUUFUVXFREBD-KKUMJFAQSA-N 0.000 description 1
- JYXBNQOKPRQNQS-YTFOTSKYSA-N Lys-Ile-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JYXBNQOKPRQNQS-YTFOTSKYSA-N 0.000 description 1
- VKCPHIOZDWUFSW-ONGXEEELSA-N Lys-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN VKCPHIOZDWUFSW-ONGXEEELSA-N 0.000 description 1
- IYXDSYWCVVXSKB-CIUDSAMLSA-N Met-Asn-Glu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O IYXDSYWCVVXSKB-CIUDSAMLSA-N 0.000 description 1
- RXWPLVRJQNWXRQ-IHRRRGAJSA-N Met-His-His Chemical compound C([C@H](NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)C1=CNC=N1 RXWPLVRJQNWXRQ-IHRRRGAJSA-N 0.000 description 1
- RDLSEGZJMYGFNS-FXQIFTODSA-N Met-Ser-Asp Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O RDLSEGZJMYGFNS-FXQIFTODSA-N 0.000 description 1
- YGNUDKAPJARTEM-GUBZILKMSA-N Met-Val-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O YGNUDKAPJARTEM-GUBZILKMSA-N 0.000 description 1
- 241000204048 Mycoplasma hominis Species 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- SWZKMTDPQXLQRD-XVSYOHENSA-N Phe-Asp-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SWZKMTDPQXLQRD-XVSYOHENSA-N 0.000 description 1
- HOYQLNNGMHXZDW-KKUMJFAQSA-N Phe-Glu-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O HOYQLNNGMHXZDW-KKUMJFAQSA-N 0.000 description 1
- YKUGPVXSDOOANW-KKUMJFAQSA-N Phe-Leu-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O YKUGPVXSDOOANW-KKUMJFAQSA-N 0.000 description 1
- WLYPRKLMRIYGPP-JYJNAYRXSA-N Phe-Lys-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=CC=C1 WLYPRKLMRIYGPP-JYJNAYRXSA-N 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- AFXCXDQNRXTSBD-FJXKBIBVSA-N Pro-Gly-Thr Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O AFXCXDQNRXTSBD-FJXKBIBVSA-N 0.000 description 1
- JUJCUYWRJMFJJF-AVGNSLFASA-N Pro-Lys-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1 JUJCUYWRJMFJJF-AVGNSLFASA-N 0.000 description 1
- FDMCIBSQRKFSTJ-RHYQMDGZSA-N Pro-Thr-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O FDMCIBSQRKFSTJ-RHYQMDGZSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- RDFQNDHEHVSONI-ZLUOBGJFSA-N Ser-Asn-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O RDFQNDHEHVSONI-ZLUOBGJFSA-N 0.000 description 1
- UOLGINIHBRIECN-FXQIFTODSA-N Ser-Glu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UOLGINIHBRIECN-FXQIFTODSA-N 0.000 description 1
- IXCHOHLPHNGFTJ-YUMQZZPRSA-N Ser-Gly-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CO)N IXCHOHLPHNGFTJ-YUMQZZPRSA-N 0.000 description 1
- GZFAWAQTEYDKII-YUMQZZPRSA-N Ser-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO GZFAWAQTEYDKII-YUMQZZPRSA-N 0.000 description 1
- ZFVFHHZBCVNLGD-GUBZILKMSA-N Ser-His-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZFVFHHZBCVNLGD-GUBZILKMSA-N 0.000 description 1
- LQESNKGTTNHZPZ-GHCJXIJMSA-N Ser-Ile-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O LQESNKGTTNHZPZ-GHCJXIJMSA-N 0.000 description 1
- PJIQEIFXZPCWOJ-FXQIFTODSA-N Ser-Pro-Asp Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O PJIQEIFXZPCWOJ-FXQIFTODSA-N 0.000 description 1
- FLONGDPORFIVQW-XGEHTFHBSA-N Ser-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FLONGDPORFIVQW-XGEHTFHBSA-N 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- XXNLGZRRSKPSGF-HTUGSXCWSA-N Thr-Gln-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N)O XXNLGZRRSKPSGF-HTUGSXCWSA-N 0.000 description 1
- WNQJTLATMXYSEL-OEAJRASXSA-N Thr-Phe-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O WNQJTLATMXYSEL-OEAJRASXSA-N 0.000 description 1
- VGYVVSQFSSKZRJ-OEAJRASXSA-N Thr-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@H](O)C)CC1=CC=CC=C1 VGYVVSQFSSKZRJ-OEAJRASXSA-N 0.000 description 1
- WTMPKZWHRCMMMT-KZVJFYERSA-N Thr-Pro-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O WTMPKZWHRCMMMT-KZVJFYERSA-N 0.000 description 1
- RPECVQBNONKZAT-WZLNRYEVSA-N Thr-Tyr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H]([C@@H](C)O)N RPECVQBNONKZAT-WZLNRYEVSA-N 0.000 description 1
- LVRFMARKDGGZMX-IZPVPAKOSA-N Thr-Tyr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=C(O)C=C1 LVRFMARKDGGZMX-IZPVPAKOSA-N 0.000 description 1
- OGOYMQWIWHGTGH-KZVJFYERSA-N Thr-Val-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O OGOYMQWIWHGTGH-KZVJFYERSA-N 0.000 description 1
- 241001502500 Trichomonadida Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- MQVGIFJSFFVGFW-XEGUGMAKSA-N Trp-Ala-Glu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O MQVGIFJSFFVGFW-XEGUGMAKSA-N 0.000 description 1
- PEVVXUGSAKEPEN-AVGNSLFASA-N Tyr-Asn-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PEVVXUGSAKEPEN-AVGNSLFASA-N 0.000 description 1
- FNWGDMZVYBVAGJ-XEGUGMAKSA-N Tyr-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC1=CC=C(C=C1)O)N FNWGDMZVYBVAGJ-XEGUGMAKSA-N 0.000 description 1
- PMHLLBKTDHQMCY-ULQDDVLXSA-N Tyr-Lys-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O PMHLLBKTDHQMCY-ULQDDVLXSA-N 0.000 description 1
- LMKKMCGTDANZTR-BZSNNMDCSA-N Tyr-Phe-Asp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LMKKMCGTDANZTR-BZSNNMDCSA-N 0.000 description 1
- GQVZBMROTPEPIF-SRVKXCTJSA-N Tyr-Ser-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GQVZBMROTPEPIF-SRVKXCTJSA-N 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- ZMDCGGKHRKNWKD-LAEOZQHASA-N Val-Asn-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ZMDCGGKHRKNWKD-LAEOZQHASA-N 0.000 description 1
- GNWUWQAVVJQREM-NHCYSSNCSA-N Val-Asn-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N GNWUWQAVVJQREM-NHCYSSNCSA-N 0.000 description 1
- QHDXUYOYTPWCSK-RCOVLWMOSA-N Val-Asp-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N QHDXUYOYTPWCSK-RCOVLWMOSA-N 0.000 description 1
- HHSILIQTHXABKM-YDHLFZDLSA-N Val-Asp-Phe Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(O)=O HHSILIQTHXABKM-YDHLFZDLSA-N 0.000 description 1
- AEMPCGRFEZTWIF-IHRRRGAJSA-N Val-Leu-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O AEMPCGRFEZTWIF-IHRRRGAJSA-N 0.000 description 1
- IJGPOONOTBNTFS-GVXVVHGQSA-N Val-Lys-Glu Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O IJGPOONOTBNTFS-GVXVVHGQSA-N 0.000 description 1
- USLVEJAHTBLSIL-CYDGBPFRSA-N Val-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C USLVEJAHTBLSIL-CYDGBPFRSA-N 0.000 description 1
- LCHZBEUVGAVMKS-RHYQMDGZSA-N Val-Thr-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(O)=O LCHZBEUVGAVMKS-RHYQMDGZSA-N 0.000 description 1
- OFTXTCGQJXTNQS-XGEHTFHBSA-N Val-Thr-Ser Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](C(C)C)N)O OFTXTCGQJXTNQS-XGEHTFHBSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 108010001271 arginyl-glutamyl-arginine Proteins 0.000 description 1
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 1
- 108010069926 arginyl-glycyl-serine Proteins 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000019628 coolness Nutrition 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- 108010057083 glutamyl-aspartyl-leucine Proteins 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010000434 glycyl-alanyl-leucine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 108010028295 histidylhistidine Proteins 0.000 description 1
- 108010018006 histidylserine Proteins 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 108010025153 lysyl-alanyl-alanine Proteins 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 108010038320 lysylphenylalanine Proteins 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- -1 nitre Azoles Chemical class 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 108010073101 phenylalanylleucine Proteins 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 108010015796 prolylisoleucine Proteins 0.000 description 1
- 108010090894 prolylleucine Proteins 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 230000009677 vaginal delivery Effects 0.000 description 1
- 208000028110 viral sexually transmitted disease Diseases 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明属于疫苗制备技术领域,具体公开了阴道毛滴虫α‑actinin重组融合蛋白免疫保护性抗原、疫苗和应用;利用原核表达体系构建了可以大量稳定表达α‑actinin亚片段的表达菌株,同时纯化并获得ACT‑T蛋白,该蛋白作为抗原免疫感染阴道毛滴虫的小鼠后,小鼠在14天后基本痊愈,对小鼠的免疫保护作用接近100%,将ACT‑T融合蛋白作为抗原制成亚单位疫苗,从而实现对小鼠的免疫保护,该疫苗具有广泛的开发应用价值。
Description
技术领域
本发明涉及疫苗制备技术领域,更具体地,涉及阴道毛滴虫α-actinin重组融合蛋白免疫保护性抗原、疫苗和应用。
背景技术
阴道毛滴虫是一种寄生于人体泌尿生殖系统的原虫。感染该虫之后会引起女性阴道炎、尿道炎、子宫颈炎;男性感染阴道毛滴虫后,发生前列腺癌的概率也比正常人群要高;阴道毛滴虫感染还会增加人群感染乙肝病毒、人型支原体以及艾滋病病毒的风险,也会引起孕妇早产以及新生儿体重偏轻,并且有可能在阴道分娩过程中传播给新生儿呼吸道。
阴道毛滴虫病呈全球分布,是最常见的非病毒性性传播疾病。然而由于缺乏对该病的充分认识和筛查计划,导致全球上百万病例未得报道及诊断,致使该病成为一种被忽视的性传播疾病。根据WHO评估,2008年全世界15至49岁年龄段的人群中,感染毛滴虫的患者约为2.764亿。相比2005年同年龄段的感染人数2.485亿,已上涨了11.2%。此外,虽然甲硝唑是目前治疗阴道毛滴虫感染的首选药物,然而,近年来除了逐渐发现甲硝唑有毒副作用以外,临床上还发现了不少甲硝唑的抗性株。由于阴道毛滴虫主要通过性接触直接传播,患者尤其是男性患者感染毛滴虫后又常为无临床症状的带虫者,可能导致其伴侣反复感染,导致交叉感染,扩大传播。因此,发展可持续控制的策略,例如疫苗的开发,就变得很有意义。而目前对于毛滴虫疫苗相关的研究非常有限。目前仅有研究人员用全虫为疫苗,或以阴道毛滴虫半胱氨酸蛋白CP62为疫苗,接种小鼠鼻腔,在小鼠的毛滴虫感染阴道模型中都有一定的保护作用。然而,与大分子抗原相比,在亚单位疫苗中,由于分子相似性而引起的自体免疫的可能性更小,因此开发亚单位疫苗更安全。
发明内容
本发明所要解决的技术问题是克服现有技术存在的上述缺陷,提供阴道毛滴虫α-actinin重组融合蛋白免疫保护性抗原。
本发明的第二个目的是提供阴道毛滴虫α-actinin重组融合蛋白免疫保护性疫苗。
本发明的第三个目的是提供上述免疫保护性抗原或疫苗的应用。
本发明的目的是通过以下技术方案予以实现的:
α-actinin重组融合蛋白ACT-T作为阴道毛滴虫病免疫保护性抗原的应用,其ACT-T的氨基酸序列如SEQ ID NO:1所示。
阴道毛滴虫α-actinin蛋白是一种结合于actin,分子大小为115Kda的蛋白,也是阴道毛滴虫细胞骨架重排中比较活跃的蛋白之一。该蛋白参与毛滴虫阿米巴形变,被认为与虫株毒力相关;并且阴道毛滴虫中最常见的免疫原就是α-actinin,可以引起了强烈的体液免疫反应,经常被发现存在于裂解的靶细胞表面。由于该蛋白强的抗原性及免疫原性,而α-actinin全基因较长,那么包含蛋白中间区域的核心抗原决定簇的亚克隆,则成为设计毛滴虫诊断与疫苗的良好选择。为获取大量纯化的目的蛋白,本研究利用BL21原核表达体系构建了可以大量稳定表达α-actinin亚片段的表达菌株,进行疫苗相关的研究。
由于α-actinin全长序列较长,在进行原核表达时多数表达为包涵体,申请人前期研究中构建了3段序列,分别是α-actinin全长序列、涵盖中间核心抗原决定簇的α-actinin全长序列前半段(ACT-F)和涵盖中间核心抗原决定簇的α-actinin全长序列后半段(ACT-T);分别将这3段序列构建表达载体进行原核表达,虽然这三段序列获得的重组蛋白均具有免疫表现,但作为免疫原对动物进行免疫时,其免疫保护作于差别显著。
申请人研究发现适当浓度的重组融合蛋白免疫感染阴道毛滴虫的小鼠后,其中ACT-T的免疫保护作于尤其明显,接近100%,因此ACT-T是制备阴道毛滴虫病疫苗理想的候选抗原。
本发明还提供α-actinin重组融合蛋白ACT-T在制备治疗阴道毛滴虫病的制剂方面的应用,其ACT-T的氨基酸序列如SEQ ID NO:1所示。
本发明还提供α-actinin重组融合蛋白ACT-T在制备预防阴道毛滴虫病的制剂方面的应用,其ACT-T的氨基酸序列如SEQ ID NO:1所示。
优选地,本发明所述ACT-T的核苷酸序列如SEQ ID NO:2所示。
本发明还提供一种阴道毛滴虫α-actinin重组融合蛋白疫苗,所述疫苗含有上述α-actinin重组融合蛋白ACT-T。
本发明所述ACT-T作为抗原免疫感染阴道毛滴虫的小鼠后,小鼠在14天后基本痊愈,本发明所述疫苗执行了主动免疫,抗原注入阴道毛滴虫的小鼠后,体内发生了复杂的免疫保护过程,从而最终实现对小鼠的免疫保护。
优选地,本发明所述疫苗还包括制备疫苗所需的辅剂。
更优选地,所述辅剂为免疫佐剂。
更优选地,所述α-actinin重组融合蛋白ACT-T的用量为20~100 ug。
与现有技术相比,本发明具有以下有益效果:
本发明提供了阴道毛滴虫α-actinin重组融合蛋白免疫保护性抗原、疫苗和应用,利用原核表达体系构建了可以大量稳定表达α-actinin亚片段的表达菌株,同时纯化并获得ACT-T蛋白,该蛋白作为抗原免疫感染阴道毛滴虫的小鼠后,小鼠在14天后基本痊愈,对小鼠的免疫保护作用接近100%,将ACT-T融合蛋白作为抗原制成亚单位疫苗,从而实现对小鼠的免疫保护,该疫苗具有广泛的开发应用价值。
附图说明
图1为阴道毛滴虫α-actinin免疫保护性抗原诱导表达和纯化后的SDS-PAGE图,其中:M为蛋白maker;泳道1,2,3分别为全长序列后半段(ACT-T)表达菌株未经IPTG诱导的菌液电泳,经过IPTG诱导的菌液电泳以及蛋白纯化后的电泳条带;泳道5,6,7分别为全长序列前半段(ACT-F)表达菌株未经IPTG诱导的菌液电泳,经过IPTG诱导的菌液电泳以及蛋白纯化后的电泳条带。
图2为将纯化的蛋白用兔抗阴道毛滴虫α-actinin多克隆抗体进western-blot检测图;其中:M为蛋白maker;泳道1为ACT-T蛋白;泳道2为ACT-F蛋白。
图3为阴道毛滴虫α-actinin免疫保护性抗原babl/c后的相对免疫保护分析图。ACT-T(HC)和ACT-T(LC)分别代表ACT-T免疫的高浓度和低浓度组;ACT-F(HC)和ACT-F(LC)分别代表ACT-F免疫的高浓度和低浓度组;FA代表佐剂与PBS等体积混合后免疫组;Control代表仅注射PBS的对照组。
图4为阴道毛滴虫α-actinin免疫保护性抗原最后一次免疫babl/c两周后的血清中特异性抗体效价间接ELISA分析结果;其中,A图是分别以ACT-T和ACT-F纯化蛋白进行包被后,血清按照1:10000稀释后的总IgG OD450nm数值;B图是分别以ACT-T和ACT-F纯化蛋白进行包被后,免疫后的小鼠血清IgG抗体滴度;C图和D图是分别以ACT-F和ACT-T纯化蛋白进行包被,检测血清抗体亚型OD450nm数值(稀释度1:1000)。
具体实施方式
下面通过实施例,并结合说明书附图对本发明进一步具体描述。下述所使用的实验方法若无特殊说明,均为本技术领域现有常规的方法,所使用的配料或材料,如无特殊说明,均为通过商业途径可得到的配料或材料;本发明不应限制于实施例范围。
实施例1 重组抗原蛋白基因序列扩增及表达载体构建
(1)将阴道毛滴虫培养液1000g离心5min,弃上清,收集约107虫体于1.5ml离心管中。加入1ml Trizol裂解液,用移液枪吹打混匀,室温静置5 min后用氯仿/异丙醇进行提取RNA,然后用RNasefree水,55~60 ℃温浴10 min溶解沉淀。
(2)除去RNA中的DNA后,用Nanodrop测RNA的A260/A280的值,确保其数值在1.8~2.0后,所测的浓度换算出RNA的原浓度。
(3)将RNA反转录为cDNA用于后续PCR扩增实验。
(4)引物设计
为达到更好的蛋白表达效果,本研究根据已公布的阴道毛滴虫a-actinin基因序列,设计两对引物,分别表达涵盖中间核心抗原决定簇的α-actinin全长序列前半段(ACT-F)和全长序列后半段(ACT-T)(表1)。
以RNA反转的cDNA为模板,以表1两对序列为引物,表2所示的条件进行PCR,得到目的基因片段,大小如表1所示。
PCR反应条件为:94℃,5min;94℃,5 sec,55℃,30 sec,72℃,2 min,35个循环;最后72℃,10min,最后进行电泳鉴定。
(5)克隆菌株构建:将阴道毛滴虫a-actinin基因电泳鉴定以后,目的片段回收,用Takara公司的A-tailing kit加上A尾,再与PCR 2.1载体连接后,导入DH5a大肠杆菌感受态细胞中。摇菌后提取质粒,克隆载体用两种限制性内切酶KpnⅠ和SalⅠ进行双酶切鉴定,并送至上海生工生物工程有限公司测序,无误后进行下一步操作。
(6)表达载体构建:用Takara公司的DNA胶回收试剂盒来回收克隆菌株中的目的基因,利用双酶切产生的粘性末端,将其与PET32a质粒连接,并将重组质粒转化入BL21菌株中。经双酶切和测序鉴定无误,即a-actinin表达菌株。测序鉴定的结果在NCBI上比对,与公布的序列匹配无误后进行诱导表达。
实施例2 重组抗原蛋白的表达纯化
一、蛋白表达条件的优化
采用单因子变量,进行以下几项的优化。通过表达条件的优化,按照摸索出来的最佳表达条件:当温度为 24℃,细菌 OD600nm值达到0.8时,分别加入终浓度为0.6 mmol/L的IPTG,持续诱导表达5 h后,阴道毛滴虫 α-actinin 基因、全长序列前半段、全长序列后半段均能取得满意的表达效果。将重组蛋白诱导与未诱菌反复冻融破碎后,用CBA蛋白浓度检测试剂盒定量,然后直接与5Xloading buffer混匀煮沸后,进行SDS-PAGE电泳,结果如图1。
二、重组蛋白纯化
重组蛋白上携带His标签,所以早期用NTA-His树脂纯化(参考Novagen组氨酸标签纯化手册),所得蛋白用于免疫新西兰白兔,获得含多克隆抗体的血清。但是后续实验中,由于蛋白用量大,全长片段形成包涵体以及组氨酸标签可能丢失,导致纯化效率不够高,所以选用电洗脱法大量纯化重组蛋白,电洗脱法的过程如下:
(1)按最优条件诱导菌液后,4℃,10000g,10min离心,弃上清。加入适量的PBS,冰浴超声破碎,超声6S,停6S,200次。加入5x1oading buffer,沸水中煮5min,分装以后放置于-20℃保存。
(2)将蛋白样品跑SDS-PAGE电泳。上样量为每块胶200ul,浓缩胶恒压80V,分离胶恒压100V,跑至溴酚蓝到胶的底部。
(3)将胶取下,用预冷的0.5mol/LKCl染胶10min,目的条带会被染成较深的乳白色。根据分子大小,切下目的条带并切碎。用电洗脱液(50mM Tris base;50mM甘氨酸;0.1%SDS;PH=8.9)将碎胶清洗至透明,然后装入清洗过的透析袋,在电洗脱液中进行电洗脱(恒压100V,4h~5h),再反向电泳(恒压100V,0.5h)。
(4)电洗脱之后将透析袋放入4℃预冷的0.1xPBS中透析,期间换液3~5次,时不时搅拌。
(5)将纯化好的蛋白溶液倒入到离心管内,-80℃冻过夜,然后放置于冷冻干燥机内进行冷冻干燥浓缩。
(6)浓缩后的蛋白用CBA蛋白浓度检测试剂盒进行蛋白定量。所有收集后的蛋白用混合在一起,用wetern-blot检测确定后,冻存于-80℃,用于后续试验。
将纯化后重组蛋白跑电泳,根据分子大小初步判断纯化后收集到的是目的蛋白,可以得到单一的条带,如图1所示,α-actinin全长序列前半段大小为70.33 kDa,α-actinin全长序列后片段大小为61.7 kDa。
上述SDS-PAGE电泳后的胶,冰浴中恒流300mA,1h转到硝酸纤维素膜上,用5%脱脂奶粉封闭过夜后,电洗脱后的蛋白用本实验室制备的兔来源多克隆抗体为一抗,37℃温育1h,TTBS 清洗3次,10min/次;羊抗小鼠IgG-HRP为二抗37℃温育1h,TBST 清洗3次,10min/次,DAB显色检测反应5~15min,置于蒸馏水中终止显色反应,抗体检测表明电洗脱方式纯化的蛋白为特异性目的蛋白,结果如图2所示。
实施例3 动物免疫以及攻毒试验
将实施例2纯化获得的蛋白作为抗原和等体积的弗氏佐剂涡旋振荡进行乳化,制备免疫原。
购买体重为20±2g的健康雌性Babl/c小鼠60只,随机分为6组。每组免疫所用小鼠数量以及小鼠皮下多点接种的蛋白量如表3所示。
所有小鼠均免疫4次。第一次为抗原与等体积弗氏完全佐剂乳化后,皮下多点注射;第二次和第三次为抗原与等体积弗氏不完全佐剂乳化后,皮下多点注射;第4次为腹腔水剂注射;第4次免疫14天后,取小鼠尾血,分离血清。并收集对数生长期的阴道毛滴虫,1×107/0.5ml/只接种于babl/c小鼠腹腔。每日观察小鼠的情况,记录发病状况及死亡时间。
结果如图3,重组蛋白免疫后的四组小鼠与未用重组蛋白免疫的两组相比,均有一定的免疫保护作用,其中ACT-T(HC)组保护作用尤为明显,近乎达到100%。因此ACT-T是制备阴道毛滴虫病疫苗理想的候选抗原,即本发明的融合蛋白ACT-T具有很好的免疫原性及免疫保护作用。
实施例4 a-actinin免疫小鼠抗体滴度情况
小鼠免疫四次后第13天取尾血0.1~0.2ml,全血置于4℃静止4~6h,离心后取上层血清,存储于-80℃;上述每组实验鼠10只按照3只、3只、4只取血清各5ul于0.5ml离心管内,轻轻混匀,制备3个间接ELISA检测抗体滴度的血清混合样品。
分别以2ug/ml纯化的重组ACT-F和ACT-T蛋白包被酶标板,以待测血清为一抗,羊抗小鼠HRP-IgG为二抗,检测各组血清抗体所产生总IgG抗体OD450nm数值及抗体滴度(图4A和B);在图中可看出血清样品稀释1:10000后,待测血清吸光值明显高于对照组,说明重组蛋白免疫小鼠后产生大量的特异性抗体,两种重组蛋白免疫产生的抗体滴度均很高。
血清样品稀释1:1000后特异抗体亚型OD450nm数值表明,特异性抗体中主要为IgG1,IgG2a亚型(图4C和D)。
抗体阳性判断根据P/N值来确定。本实验中待测血清OD450nm数值(P)与阴性血清OD450nm数值(N)的比值大于3,则在本实验中确定为阳性。
综上所述,本发明的阴道毛滴虫α-actinin免疫保护性、抗原免疫原性很好,为阴道毛滴虫病小鼠模型提供一种有效的免疫保护作用,可作为具有重要价值的抗阴道毛滴虫病候选疫苗用于后续开。
SEQUENCE LISTING
<110> 中山大学
<120> 阴道毛滴虫α-actinin蛋白免疫保护性抗原、疫苗和应用
<130>
<160> 6
<170> PatentIn version 3.3
<210> 1
<211> 550
<212> PRT
<213> ACT-T氨基酸序列
<400> 1
Met Ser Asp Lys Ile Ile His Leu Thr Asp Asp Ser Phe Asp Thr Asp
1 5 10 15
Val Leu Lys Ala Asp Gly Ala Ile Leu Val Asp Phe Trp Ala Glu Trp
20 25 30
Cys Gly Pro Cys Lys Met Ile Ala Pro Ile Leu Asp Glu Ile Ala Asp
35 40 45
Glu Tyr Gln Gly Lys Leu Thr Val Ala Lys Leu Asn Ile Asp Gln Asn
50 55 60
Pro Gly Thr Ala Pro Lys Tyr Gly Ile Arg Gly Ile Pro Thr Leu Leu
65 70 75 80
Leu Phe Lys Asn Gly Glu Val Ala Ala Thr Lys Val Gly Ala Leu Ser
85 90 95
Lys Gly Gln Leu Lys Glu Phe Leu Asp Ala Asn Leu Ala Gly Ser Gly
100 105 110
Ser Gly His Met His His His His His His Ser Ser Gly Leu Val Pro
115 120 125
Arg Gly Ser Gly Met Lys Glu Thr Ala Ala Ala Lys Phe Glu Arg Gln
130 135 140
His Met Asp Ser Pro Asp Leu Gly Thr Thr Tyr Ile Lys His Leu Leu
145 150 155 160
Glu Gln Leu Asn Gly Lys Leu Phe Glu Glu Thr Asn Glu Ala Arg Ile
165 170 175
Asn Glu Tyr Asn Ala Leu Ala Gln Pro Leu Tyr Asp Glu Ala Ile Ala
180 185 190
Phe Lys Glu Glu Val Leu Ala Ile Ser Gly Glu Leu Arg Glu Arg Arg
195 200 205
Thr Gln Phe Leu Ala Lys Gln Ala Glu Ala Pro Thr Lys Arg Glu His
210 215 220
Val Asn Glu Ile Asp Pro Ile Phe Asp Gly Leu Glu Lys Asp Ser Leu
225 230 235 240
His Leu Arg Val Asn His Ser Pro Thr Glu Ile Arg Asn Val Tyr Ala
245 250 255
Val Thr Leu Gln His Ile Ile Thr Glu Leu Asn Lys Ile Phe Glu Glu
260 265 270
Met Val Ala Asn Phe Asp Ala Thr Ala Val Pro Ile Ile Asp Gly Ile
275 280 285
Thr Ala Leu Val Thr Ser Ser His Gln Ile Pro Gly Asp Ala Ala Ala
290 295 300
Val Lys Ala Gln Val Glu Glu Asn Leu Ala Ser Leu Asp Gly Phe Ala
305 310 315 320
Glu Lys Ile Gln Ala Leu Gln Asp Pro Tyr Asn Glu Leu Val Glu Phe
325 330 335
Lys Leu Asn Tyr Lys Val Thr Tyr Thr Tyr Ser Asp Ala Thr Gly Glu
340 345 350
Leu Asp Gln Ala Arg Leu Asp Leu Lys Gln Ile Ile Leu Ala Lys Lys
355 360 365
Thr Phe Leu Glu Glu Glu Glu Arg Lys Ala Arg Ile Asn Asn Tyr Thr
370 375 380
Val Lys Ala Asp Glu His Met Asn Glu Ala His Ala Leu Asp Gly Lys
385 390 395 400
Ile Asn Ser Val Asp Gly Glu Leu Glu Pro Lys Arg Gln Lys Leu Tyr
405 410 415
Glu Val Arg Glu Glu Val Asn Ala Lys Lys Glu Lys Ala Ala Glu Glu
420 425 430
Leu Thr Pro Ile Tyr Glu Asp Leu Glu Lys Asp Gln Leu His Leu Glu
435 440 445
Ile Thr Ser Thr Pro Ala Ser Ile Asn Ile Phe Phe Glu Asn Leu Ile
450 455 460
Ala His Ile Asp Thr Leu Val Lys Glu Ile Asp Ala Ala Ile Ala Ala
465 470 475 480
Ala Lys Gly Leu Glu Ile Ser Glu Glu Glu Leu Asn Glu Phe Lys Asp
485 490 495
Thr Phe Lys Tyr Phe Asp Lys Asp Lys Ser Asn Ser Leu Glu Tyr Phe
500 505 510
Glu Leu Lys Ala Cys Leu Thr Ala Leu Gly Glu Asp Ile Thr Asp Asp
515 520 525
Gln Ala Lys Glu Tyr Cys Lys Val Asp Lys Leu Ala Ala Ala Leu Glu
530 535 540
His His His His His His
545 550
<210> 2
<211> 1653
<212> DNA
<213> ACT-T核苷酸序列
<400> 2
atgagcgata aaattattca cctgactgac gacagttttg acacggatgt actcaaagcg 60
gacggggcga tcctcgtcga tttctgggca gagtggtgcg gtccgtgcaa aatgatcgcc 120
ccgattctgg atgaaatcgc tgacgaatat cagggcaaac tgaccgttgc aaaactgaac 180
atcgatcaaa accctggcac tgcgccgaaa tatggcatcc gtggtatccc gactctgctg 240
ctgttcaaaa acggtgaagt ggcggcaacc aaagtgggtg cactgtctaa aggtcagttg 300
aaagagttcc tcgacgctaa cctggccggt tctggttctg gccatatgca ccatcatcat 360
catcattctt ctggtctggt gccacgcggt tctggtatga aagaaaccgc tgctgctaaa 420
ttcgaacgcc agcacatgga cagcccagat ctgggtacca catacatcaa gcacctcctc 480
gagcagctca acggcaagct cttcgaagag acaaacgagg cccgcatcaa cgagtacaac 540
gctcttgccc agccactcta cgacgaggcc atcgccttca aggaggaagt cttagccatc 600
agcggcaaac tccgcgagcg ccgtacacag ttcctcgcca agcaggctga ggctccaaca 660
aagagagagc acgttaacga gatcgaccca atcttcgacg gactcgagaa ggattcactt 720
cacctccgtg tcaaccaaag cccaacagaa atccgtaacg tttacgctgt tacacttcag 780
cacatcatca cagaactcaa caagatcttc gaggagatgg ttgccaactt cgatgccacc 840
gctgtcccaa tcatcgatgg tatcacagcc ctcgtcacat cctcccacca gatcccagga 900
gatgctgctg cagtcaaggc tcaggttgag gagaacctcg cttccctcga tggcttcgct 960
gaaaagatcc aagccctcca ggatccatac aacgagctcg ttgaattcaa gctcaactac 1020
aaggtcacat acacatactc tgatgctact ggtgaactcg atcaggcacg tcttgacctc 1080
aagcagatca tcctcgccaa gaagacattc ctcgaggaag aagagcgcaa ggcccgcatc 1140
aacaactaca cagtcaaggc tgacgagcac atgaacgagg ctcatgctct cgatggcaag 1200
atcaactccg tcgatggcga actcgaacca aagagacaga aactctacga agtccgtgag 1260
gaagtcaacg ccaagaagga gaaggccgtc gaggaactca caccaatcta cgaagacctc 1320
gaaaaggatc agctccatct cgaaatcaca tccacaccag cttccatcaa catcttcttc 1380
gagaacctca tcgcccacat cgatacactc gtcaaggaaa tcgatgctgc tatcgctgct 1440
gctaagggtc tcgagatctc cgaagaagaa ctcaacgagt tcaaggatac attcaagtac 1500
ttcgacaagg ataaatccaa ctccctcgag tacttcgaac tcaaggcttg ccttacagct 1560
ctcggcgaag atatcacaga tgaccaggct aaggaatact gcaaggtcga caagcttgcg 1620
gccgcactcg agcaccacca ccaccaccac tga 1653
<210> 3
<211> 30
<212> DNA
<213> ACT-F正向引物
<400> 3
gacggtaccg agaagaccca gatcaaggtt 30
<210> 4
<211> 30
<212> DNA
<213> ACT-F反向引物
<400> 4
agtgtcgacg aggaggtgct tgatgtatgt 30
<210> 5
<211> 30
<212> DNA
<213> ACT-T正向引物
<400> 5
gacggtacca catacatcaa gcacctcctc 30
<210> 6
<211> 30
<212> DNA
<213> ACT-T反向引物
<400> 6
agtgtcgacc ttgcagtatt ccttagcctg 30
Claims (8)
1.α-actinin重组融合蛋白ACT-T用于制备阴道毛滴虫病免疫保护性抗原药物的应用,其特征在于,其ACT-T的氨基酸序列如SEQ ID NO:1所示。
2. α-actinin重组融合蛋白ACT-T在制备治疗阴道毛滴虫病的制剂方面的应用,其特征在于,其ACT-T的氨基酸序列如SEQ ID NO:1所示。
3. α-actinin重组融合蛋白ACT-T在制备预防阴道毛滴虫病的制剂方面的应用,其特征在于,其ACT-T的氨基酸序列如SEQ ID NO:1所示。
4. 根据权利要求1至3任一项所述的应用,其特征在于,编码所述ACT-T蛋白的核苷酸序列如SEQ ID NO:2所示。
5.一种阴道毛滴虫α-actinin重组融合蛋白疫苗,其特征在于,所述疫苗含有权利要求1所述α-actinin重组融合蛋白ACT-T。
6.根据权利要求5所述的疫苗,其特征在于,还包括制备疫苗所需的辅剂。
7.根据权利要求6所述的疫苗,其特征在于,所述辅剂为免疫佐剂。
8. 根据权利要求6所述的疫苗,其特征在于,所述α-actinin重组融合蛋白ACT-T的用量为20~100 μg。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510742631.5A CN105237632B (zh) | 2015-11-04 | 2015-11-04 | 阴道毛滴虫α-actinin蛋白免疫保护性抗原、疫苗和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510742631.5A CN105237632B (zh) | 2015-11-04 | 2015-11-04 | 阴道毛滴虫α-actinin蛋白免疫保护性抗原、疫苗和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105237632A CN105237632A (zh) | 2016-01-13 |
CN105237632B true CN105237632B (zh) | 2018-11-27 |
Family
ID=55035494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510742631.5A Active CN105237632B (zh) | 2015-11-04 | 2015-11-04 | 阴道毛滴虫α-actinin蛋白免疫保护性抗原、疫苗和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105237632B (zh) |
-
2015
- 2015-11-04 CN CN201510742631.5A patent/CN105237632B/zh active Active
Non-Patent Citations (2)
Title |
---|
Immunogenic proteins of Trichomonas vaginalis as demonstrated by the immunoblot technique;G E Garber et al.;《Infect. Immun. 》;19860131;第51卷(第1期);第250-253页 * |
阴道毛滴虫可溶性抗原组分分析;李玉峰;《中国优秀硕士学位论文全文数据库 医药卫生科技辑》;20071115(第5期);全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN105237632A (zh) | 2016-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105669838B (zh) | 来自水痘-带状疱疹病毒gE蛋白的中和表位及针对其的抗体 | |
JP6294828B2 (ja) | インフルエンザウイルスワクチンおよびその使用 | |
CN106046155B (zh) | 用于治疗hbv感染及相关疾病的多肽及抗体 | |
CN109575126B (zh) | 多肽、其生产方法和用途 | |
CN113943375B (zh) | 一类来源于新型冠状病毒s2蛋白hr区域的重组融合蛋白及其应用 | |
CN107033250B (zh) | 牛冠状病毒重组多表位抗原及其应用 | |
CN108586607A (zh) | 抗hpv16 l1蛋白单克隆抗体的制备方法及其应用 | |
CN107841507A (zh) | 一种高效表达的猪圆环病毒2型Cap‑穿膜肽融合蛋白基因及其应用 | |
CN105106945B (zh) | 一种幽门螺旋杆菌四价毒力因子多表位疫苗及其制备方法 | |
CN114874995A (zh) | 猪瘟病毒2型Erns蛋白的单克隆抗体杂交瘤细胞株及应用 | |
CN107586322B (zh) | 牛传染性鼻气管炎病毒gD蛋白抗原表位多肽及其抑制剂和单抗及其应用 | |
CN102558348B (zh) | 一种抗流感病毒的单链抗体及其制备方法和应用 | |
CN114524862B (zh) | 禽流感(h5+h7)三价dna疫苗的构建及其应用 | |
CN106279431B (zh) | 一种猪圆环病毒亚单位灭活疫苗 | |
CN103642792B (zh) | 一种抗丙肝病毒的中和性单克隆抗体的制备及其应用 | |
CN104694479B (zh) | 肠道病毒71型的vp2抗原的中和表位多肽及其用途 | |
WO2022068846A1 (zh) | 新型冠状病毒mRNA疫苗及其制备方法与应用 | |
JP2018052953A (ja) | インフルエンザウイルスワクチンおよびその使用 | |
CN102134278A (zh) | 圆环病毒基因工程黏膜免疫亚单位疫苗的制备及其应用 | |
CN105237632B (zh) | 阴道毛滴虫α-actinin蛋白免疫保护性抗原、疫苗和应用 | |
CN104611343B (zh) | 分离的鲤抗病毒天然免疫蛋白trim32及抗病毒活性 | |
CN101070347B (zh) | 禽流感h5n1新型粘膜免疫疫苗及其应用 | |
Chen et al. | Development and evaluation of nucleoprotein-based rapid detection test for Siniperca chuatsi rhabdovirus | |
CN106397602B (zh) | 一种分子佐剂加强型鸡马立克氏病蛋白工程疫苗 | |
CN103131719B (zh) | 具有免疫保护性的脑多头带绦虫烯醇酶TmENO重组蛋白 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Lun Zhaorong Inventor after: Lai Dehua Inventor after: Xie Daiting Inventor after: Wu Yaping Inventor after: Wang Zhenjie Inventor before: Lun Zhaorong Inventor before: Xie Daiting Inventor before: Zhang Jia Inventor before: Wu Yaping Inventor before: Wang Zhenjie |
|
COR | Change of bibliographic data | ||
GR01 | Patent grant | ||
GR01 | Patent grant |